← Back to Clinical Trials
Recruiting Phase 4 NCT07023094

PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Hip Disease
Sponsor Poznan University of Medical Sciences
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 60
Sex ALL
Min Age 2 Years
Max Age 16 Years
Start Date 2025-06-16
Completion 2026-05-30
Interventions
Ropivacaine 0.2% for PENG BlockRopivacaine 0.2% for LFCBRopivacaine 0.2% for L-ESPB

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.

Eligibility Criteria

Inclusion Criteria: * Pediatric patients aged between 2 and 16 years. * Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries * ASA (American Society of Anesthesiologists) physical status classification: I-III. * Written informed consent obtained from the patient's legal guardian(s). Exclusion Criteria: * Known allergy or hypersensitivity to any of the study medications * Presence of infection or inflammation at the intended injection site(s) of regional anesthesia. * Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks. * Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs. * Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation. * History of chronic opioid use or known substance abuse. * Severe systemic disease or condition compromising patient safety or in

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}